Loading...
•
Mar 31, 2022
OrthoPediatrics Q1 2022 Earnings Report
OrthoPediatrics reported a revenue increase of 9% year-over-year, driven by growth in trauma and deformity, and scoliosis segments. The company increased its full-year revenue guidance for 2022.
Key Takeaways
OrthoPediatrics Corp. reported a 9% increase in revenue for Q1 2022, reaching $23.4 million compared to $21.5 million in Q1 2021. The company's U.S. revenue increased by 8%, while international revenue grew by 13%. Trauma and Deformity revenue increased by 13%, Scoliosis revenue increased by 1%, and Sports Medicine/Other revenue decreased by 4%. The company has increased its full year 2022 revenue guidance to $122 million to $125 million.
Total revenue reached $23.4 million, a 9% increase year-over-year.
U.S. revenue increased by 8%, while international revenue grew by 13%.
Trauma and Deformity revenue increased by 13%, Scoliosis revenue increased by 1%.
Full year 2022 revenue guidance increased to $122 million to $125 million.
OrthoPediatrics
OrthoPediatrics
OrthoPediatrics Revenue by Segment
OrthoPediatrics Revenue by Geographic Location
Revenue by Segment
Trauma & Deformity Revenue
CapyFin.comScoliosis Revenue
CapyFin.comSports Medicine/Other Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
For full year 2022, the Company now expects its full year revenue to be in the range of $122 million to $125 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income